(Reuters) – Eli Lilly anticipates to begin offering its weight-loss medicine in Hong Kong as early as completion of this year, Bloomberg News reported on Sunday.
The business has actually gotten the Hong Kong federal government authorization to market its tirzepatide shots– branded as Mounjaro– in a gadget called Kwikpen for both long-lasting weight administration and kind 2 diabetes mellitus, Eli Lilly informed Bloomberg in a declaration.
(Reporting by Jahnavi Nidumolu in Bengaluru)
